HU221006B1 - Eljárás thymosin és/vagy thymosin-fragmentumot tartalmazó, hepatitisz C kezelésére szolgáló gyógyszerkészítmény előállítására - Google Patents
Eljárás thymosin és/vagy thymosin-fragmentumot tartalmazó, hepatitisz C kezelésére szolgáló gyógyszerkészítmény előállítására Download PDFInfo
- Publication number
- HU221006B1 HU221006B1 HU9400758A HU9400758A HU221006B1 HU 221006 B1 HU221006 B1 HU 221006B1 HU 9400758 A HU9400758 A HU 9400758A HU 9400758 A HU9400758 A HU 9400758A HU 221006 B1 HU221006 B1 HU 221006B1
- Authority
- HU
- Hungary
- Prior art keywords
- patients
- thymosin
- hepatitis
- treatment
- interferon
- Prior art date
Links
- 108010046075 Thymosin Proteins 0.000 title claims abstract description 33
- 102000007501 Thymosin Human genes 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims abstract description 14
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 title claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- 208000005176 Hepatitis C Diseases 0.000 title abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 241000711549 Hepacivirus C Species 0.000 claims description 24
- 108700016958 thymosin fraction 5 Proteins 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- 238000011282 treatment Methods 0.000 abstract description 48
- 102000014150 Interferons Human genes 0.000 abstract description 23
- 108010050904 Interferons Proteins 0.000 abstract description 23
- 229940079322 interferon Drugs 0.000 abstract description 16
- 229940047124 interferons Drugs 0.000 abstract description 7
- 241000124008 Mammalia Species 0.000 abstract description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 29
- 108010082126 Alanine transaminase Proteins 0.000 description 29
- 210000002966 serum Anatomy 0.000 description 24
- 230000004044 response Effects 0.000 description 15
- 102000006992 Interferon-alpha Human genes 0.000 description 14
- 108010047761 Interferon-alpha Proteins 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 208000006454 hepatitis Diseases 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 231100000283 hepatitis Toxicity 0.000 description 9
- 208000010710 hepatitis C virus infection Diseases 0.000 description 9
- 208000006154 Chronic hepatitis C Diseases 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 230000006872 improvement Effects 0.000 description 6
- 238000012317 liver biopsy Methods 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- -1 fibroblasts Proteins 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 206010019799 Hepatitis viral Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 201000001862 viral hepatitis Diseases 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 206010019755 Hepatitis chronic active Diseases 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 238000009533 lab test Methods 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010019791 Hepatitis post transfusion Diseases 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 101710127454 Interferon alpha-3 Proteins 0.000 description 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010078233 Thymalfasin Proteins 0.000 description 2
- 102400000800 Thymosin alpha-1 Human genes 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 208000005252 hepatitis A Diseases 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 229950000038 interferon alfa Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 2
- 229960004231 thymalfasin Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 206010065051 Acute hepatitis C Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 208000037621 acute hepatitis C virus infection Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 150000004688 heptahydrates Chemical class 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000008935 histological improvement Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000003041 necroinflammatory effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Beans For Foods Or Fodder (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75954491A | 1991-09-13 | 1991-09-13 | |
| PCT/US1992/007556 WO1993005806A1 (en) | 1991-09-13 | 1992-09-08 | Composition and method of treating hepatitis c |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HU9400758D0 HU9400758D0 (en) | 1994-06-28 |
| HUT75166A HUT75166A (en) | 1997-04-28 |
| HU221006B1 true HU221006B1 (hu) | 2002-07-29 |
Family
ID=25056052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9400758A HU221006B1 (hu) | 1991-09-13 | 1992-09-08 | Eljárás thymosin és/vagy thymosin-fragmentumot tartalmazó, hepatitisz C kezelésére szolgáló gyógyszerkészítmény előállítására |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US6001799A (enExample) |
| EP (1) | EP0603305B1 (enExample) |
| JP (1) | JP3228512B2 (enExample) |
| KR (1) | KR100254082B1 (enExample) |
| AT (1) | ATE152914T1 (enExample) |
| AU (1) | AU667327B2 (enExample) |
| CA (1) | CA2119006C (enExample) |
| CZ (1) | CZ286827B6 (enExample) |
| DE (1) | DE69219782T2 (enExample) |
| DK (1) | DK0603305T3 (enExample) |
| ES (1) | ES2103966T3 (enExample) |
| FI (1) | FI107879B (enExample) |
| GR (1) | GR3024025T3 (enExample) |
| HK (1) | HK1021687A1 (enExample) |
| HU (1) | HU221006B1 (enExample) |
| MX (1) | MX9205240A (enExample) |
| NO (1) | NO941310L (enExample) |
| RO (1) | RO111991B1 (enExample) |
| RU (1) | RU2104010C1 (enExample) |
| SG (1) | SG64897A1 (enExample) |
| TW (1) | TW224053B (enExample) |
| WO (1) | WO1993005806A1 (enExample) |
| ZA (1) | ZA926964B (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW224053B (enExample) * | 1991-09-13 | 1994-05-21 | Paul B Chretien | |
| WO1995011688A1 (en) * | 1992-02-06 | 1995-05-04 | Sciclone Pharmaceuticals | Method for treating hepatitis b carriers with minimal disease |
| WO1994001125A1 (en) * | 1992-07-13 | 1994-01-20 | Sherman Kenneth E | Composition and method of treating hepatitis b |
| AU751199B2 (en) * | 1992-07-13 | 2002-08-08 | Government Of The United States Of America As Represented By The Secretary Of The Army | Composition and method of treating hepatitis B |
| CN1072961C (zh) * | 1993-03-05 | 2001-10-17 | 施塞克龙药品公司 | 治疗对干扰素治疗无反应者的丙型肝炎的方法 |
| US6200952B1 (en) | 1993-06-02 | 2001-03-13 | Sciclone Pharmaceuticals, Inc. | Combination therapy method for treating chronic hepatitis B |
| TW249754B (enExample) * | 1993-10-26 | 1995-06-21 | Alpha I Biomedicals Inc | |
| EP0731710B1 (en) * | 1993-11-05 | 2003-05-14 | Alpha 1 Biomedicals, Inc. | Thymosine alpha 1 containing compositions for the treatment of patients having decompensated liver disease |
| JP3837769B2 (ja) * | 1995-06-12 | 2006-10-25 | 大塚製薬株式会社 | 抗ウイルス剤 |
| DK0886527T3 (da) * | 1996-02-28 | 2002-03-04 | Unihart Corp | Farmaceutiske sammensætninger indeholdende naturligt humant alfa-interferon |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| JP5230052B2 (ja) | 2000-05-26 | 2013-07-10 | イデニクス（ケイマン）リミテツド | フラビウイルスおよびペスチウイルス治療のための方法および組成物 |
| US7208167B2 (en) * | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
| AU8353601A (en) * | 2000-08-07 | 2002-02-18 | Sciclone Pharmaceuticals Inc | Treatment of hepatitis c with thymosin, interferon and ribavirin |
| US6878364B2 (en) * | 2000-12-01 | 2005-04-12 | Cornell Research Foundation, Inc. | Animal model for flaviviridae infection |
| RU2211703C2 (ru) * | 2001-06-08 | 2003-09-10 | ООО НТЦ "Юпитер-2" | Антистрессорное и ноотропное средство с антивирусным и иммуностимулирующим действием |
| WO2003026589A2 (en) * | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
| JP2005508935A (ja) * | 2001-10-05 | 2005-04-07 | インターミューン インコーポレイテッド | 肝線維症およびｃ型肝炎ウイルス感染症を治療する方法 |
| DE60224435T2 (de) * | 2001-10-26 | 2009-01-02 | Rhode Island Hospital | Thymosin-augmentation bei genetischer immunisierung |
| UA80957C2 (en) * | 2001-11-01 | 2007-11-26 | Sciclone Pharmaceuticals Inc | Method of administering a thymosin alpha 1 peptide |
| WO2003068162A2 (en) * | 2002-02-14 | 2003-08-21 | Pharmasset Ltd. | Modified fluorinated nucleoside analogues |
| AP2005003213A0 (en) | 2002-06-28 | 2005-03-31 | Univ Cagliari | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections. |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| NZ537662A (en) | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| TW200500375A (en) | 2002-06-28 | 2005-01-01 | Idenix Cayman Ltd | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae |
| US7824851B2 (en) | 2002-11-15 | 2010-11-02 | Idenix Pharmaceuticals, Inc. | 2′-branched nucleosides and Flaviviridae mutation |
| MXPA05006230A (es) | 2002-12-12 | 2005-09-20 | Idenix Cayman Ltd | Proceso para la produccion de nucleosidos ramificados-2'. |
| GB0301879D0 (en) * | 2003-01-27 | 2003-02-26 | Regent Res Llp | HCV combination therapy |
| JP4149296B2 (ja) * | 2003-03-26 | 2008-09-10 | 株式会社ルネサステクノロジ | 半導体記憶装置 |
| ES2345552T3 (es) * | 2003-03-28 | 2010-09-27 | Sciclone Pharmaceuticals, Inc. | Tratamiento de infecciones por aspergillus con timosina alfa 1. |
| EP1613340B1 (en) | 2003-03-28 | 2010-05-12 | SciClone Pharmaceuticals, Inc. | Treatment of aspergillus infections with thymosin alpha 1 |
| US20100311656A1 (en) * | 2003-04-23 | 2010-12-09 | Sciclone Pharmaceuticals, Inc. | Treatment or prevention of respiratory viral infections with alpha thymosin peptides |
| CN100503628C (zh) | 2003-05-30 | 2009-06-24 | 法莫赛特股份有限公司 | 修饰的氟化核苷类似物 |
| CN1852915A (zh) * | 2003-07-25 | 2006-10-25 | 艾登尼科斯（开曼）有限公司 | 治疗包括丙型肝炎的黄病毒科病毒所致疾病的嘌呤核苷类似物 |
| WO2005021007A1 (fr) * | 2003-08-28 | 2005-03-10 | Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' | Prevention et traitement de l'hepatite virale b |
| WO2005107742A1 (en) | 2004-05-05 | 2005-11-17 | Yale University | Novel antiviral helioxanthin analogs |
| CN101023094B (zh) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
| BRPI0515279A (pt) | 2004-09-14 | 2008-07-15 | Pharmasset Inc | preparação de ribofuranosil pirimidinas e purinas 2'fluoro-2'-alquil- substituìdas ou outras opcionalmente substituìdas e seus derivados |
| JP4516863B2 (ja) * | 2005-03-11 | 2010-08-04 | 株式会社ケンウッド | 音声合成装置、音声合成方法及びプログラム |
| ES2422290T3 (es) | 2005-12-23 | 2013-09-10 | Idenix Pharmaceuticals Inc | Procedimiento para preparar un producto intermedio sintético para la preparación de nucleósidos ramificados |
| EP1832295A1 (en) * | 2006-03-10 | 2007-09-12 | Tecnogen S.P.A. | Use of PTX3 for the treatment of viral diseases |
| CN101437535B (zh) * | 2006-05-02 | 2013-01-30 | 希格马托制药工业公司 | 胸腺素α1单独地或与PTX3或更昔洛韦联合在治疗巨细胞病毒感染中的用途 |
| ES2288118B1 (es) * | 2006-05-10 | 2008-11-01 | Bcn Peptides, S.A. | Procedimiento para sintetizar timosinas. |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| TW200946541A (en) * | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| EP2349315A4 (en) * | 2008-10-08 | 2012-07-04 | Univ Miami | LYMPHOCYTE REGULATION AND APPLICATION |
| EP2376515A1 (en) | 2008-12-23 | 2011-10-19 | Pharmasset, Inc. | Synthesis of purine nucleosides |
| US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
| CA2748057C (en) | 2008-12-23 | 2018-07-03 | Pharmasset, Inc. | Nucleoside phosphoramidates |
| CN102458470B (zh) | 2009-05-08 | 2016-01-20 | 赛生制药有限公司 | 作为疫苗增强剂的α胸腺素肽 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
| CL2011000718A1 (es) | 2010-03-31 | 2012-04-09 | Gilead Pharmasset Llc | Proceso para la preparacion de compuestos fosforados enantiomericos. |
| PT3042910T (pt) | 2010-11-30 | 2019-04-16 | Gilead Pharmasset Llc | 2'-espiro-nucleósidos para utilização na terapia da hepatite c |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| US8809354B2 (en) | 2011-12-31 | 2014-08-19 | Sheikh Riazuddin | 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections |
| CN103800293B (zh) * | 2012-11-09 | 2015-10-21 | 长春海悦药业有限公司 | 一种含有胸腺法新的药物组合物及其制剂 |
| EP3650014B1 (en) | 2013-08-27 | 2021-10-06 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1216056B (it) * | 1988-03-11 | 1990-02-22 | Sclavo Spa | Composizioni farmaceutiche contenenti timosina alfa 1. |
| US5273963A (en) * | 1991-03-29 | 1993-12-28 | The George Washington University | Compositions and methods for treating small cell and nonsmall cell lung cancers |
| TW224053B (enExample) * | 1991-09-13 | 1994-05-21 | Paul B Chretien |
-
1992
- 1992-03-16 TW TW081101971A patent/TW224053B/zh active
- 1992-09-08 DE DE69219782T patent/DE69219782T2/de not_active Expired - Lifetime
- 1992-09-08 CA CA002119006A patent/CA2119006C/en not_active Expired - Lifetime
- 1992-09-08 RO RO94-00409A patent/RO111991B1/ro unknown
- 1992-09-08 RU RU94022480A patent/RU2104010C1/ru active
- 1992-09-08 AU AU26447/92A patent/AU667327B2/en not_active Ceased
- 1992-09-08 WO PCT/US1992/007556 patent/WO1993005806A1/en not_active Ceased
- 1992-09-08 DK DK92919977.6T patent/DK0603305T3/da active
- 1992-09-08 HK HK98105712A patent/HK1021687A1/en not_active IP Right Cessation
- 1992-09-08 CZ CZ1994551A patent/CZ286827B6/cs not_active IP Right Cessation
- 1992-09-08 JP JP50608393A patent/JP3228512B2/ja not_active Expired - Fee Related
- 1992-09-08 ES ES92919977T patent/ES2103966T3/es not_active Expired - Lifetime
- 1992-09-08 HU HU9400758A patent/HU221006B1/hu not_active IP Right Cessation
- 1992-09-08 AT AT92919977T patent/ATE152914T1/de active
- 1992-09-08 SG SG1996006295A patent/SG64897A1/en unknown
- 1992-09-08 KR KR1019940700603A patent/KR100254082B1/ko not_active Expired - Fee Related
- 1992-09-08 EP EP92919977A patent/EP0603305B1/en not_active Expired - Lifetime
- 1992-09-11 ZA ZA926964A patent/ZA926964B/xx unknown
- 1992-09-14 MX MX9205240A patent/MX9205240A/es not_active IP Right Cessation
-
1993
- 1993-03-05 US US08/027,500 patent/US6001799A/en not_active Expired - Lifetime
- 1993-11-04 US US08/145,660 patent/US5849696A/en not_active Expired - Lifetime
-
1994
- 1994-03-10 FI FI941133A patent/FI107879B/fi not_active IP Right Cessation
- 1994-04-12 NO NO941310A patent/NO941310L/no unknown
-
1997
- 1997-07-09 GR GR970401680T patent/GR3024025T3/el unknown
-
2007
- 2007-05-11 US US11/801,834 patent/US20070218033A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU221006B1 (hu) | Eljárás thymosin és/vagy thymosin-fragmentumot tartalmazó, hepatitisz C kezelésére szolgáló gyógyszerkészítmény előállítására | |
| HK1021687B (en) | Use of a thymosin in the treatment of hepatitis c | |
| Douglas et al. | Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C: comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM | |
| Ruiz-Moreno et al. | Levamisole and interferon in children with chronic hepatitis B | |
| WO1994001125A1 (en) | Composition and method of treating hepatitis b | |
| WO1994001125A9 (en) | Composition and method of treating hepatitis b | |
| EP0687181B1 (en) | Use of thymosin for treating hepatitis c in non-responders to interferon treatment | |
| Fattovich et al. | Therapy for chronic hepatitis B with lymphoblastoid interferon‐α and levamisole | |
| Farhat et al. | Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B | |
| Fattovich et al. | A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B | |
| Mauser‐Bunschoten et al. | Effect and side‐effects of alpha interferon treatment in haemophilia patients with chronic hepatitis C | |
| JPH07258109A (ja) | Ｃ型肝炎の処置法および処置用組成物 | |
| AU751199B2 (en) | Composition and method of treating hepatitis B | |
| JPH072693A (ja) | 肝炎処置用医薬組成物 | |
| WO2013138064A1 (en) | Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DGB9 | Succession in title of applicant |
Owner name: SCICLONE PHARMACEUTICALS INC., US |
|
| MM4A | Lapse of definitive patent protection due to non-payment of fees |